{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:46:30Z","timestamp":1786977990271,"version":"build-2736575974"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Efgartigimod represents a first\u2010in\u2010class immunomodulatory agent that is comparable to TPE in reducing immunoglobulin levels. This translates to reductions in Myasthenia Gravis symptom scores with maximal effect following the fourth weekly efgartigimod dose. Efgartigimod received FDA approval in December of 2021 and may be an alternative particularly for patients on long\u2010term TPE regimens of weekly or less frequent. Apheresis practitioners, especially those managing long\u2010term apheresis in seropositive individuals, may therefore see some of their patients transitioned from plasma exchange to efgartigimod. Long\u2010term experience with efgartigimod remains lacking and studies are needed to establish the role of efgartigimod in the acute setting.<\/jats:p>","DOI":"10.1002\/jca.22002","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T04:49:22Z","timestamp":1661230162000},"page":"512-515","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["\u201cPlasma exchange in a bottle\u201d: An overview of efgartigimod for apheresis practitioners"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9974-5277","authenticated-orcid":false,"given":"Minh\u2010Ha","family":"Tran","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of California, Irvine School of Medicine  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9468-4"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1009433"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"},{"key":"e_1_2_4_11_1","unstructured":"Vyvgart Package Insert https:\/\/www.argenx.com\/product\/vyvgart-prescribing-information.pdf"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3"},{"issue":"1","key":"e_1_2_4_13_1","first-page":"119","article-title":"The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis","volume":"28","author":"Tice JA","year":"2022","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.22002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jca.22002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.22002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:56:39Z","timestamp":1692622599000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.22002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/jca.22002"],"URL":"https:\/\/doi.org\/10.1002\/jca.22002","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"2022-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}